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ABSTRACT
Clinically useful molecular tools to triage gastric cancer patients are not
currently available. We aimed to develop a molecular tool to predict gastric cancer
risk in endoscopy-driven biopsies obtained from high-risk gastric cancer clinics in low
resource settings.
We discovered and validated a DNA methylation biomarker panel in endoscopic
samples obtained from 362 patients seen between 2004 and 2009 in three high-risk
gastric cancer clinics in Lima, Perú, and validated it in 306 samples from the Cancer
Genome Atlas project (“TCGA”). Global, epigenome wide and gene-specific DNA
methylation analyses were used in a Phase I Biomarker Development Trial to identify
a continuous biomarker panel that combines a Global DNA Methylation Index (GDMI)
and promoter DNA methylation levels of IRF4, ELMO1, CLIP4 and MSC.
We observed an inverse association between the GDMI and histological
www.impactjournals.com/oncotarget
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progression to gastric cancer, when comparing gastritis patients without metaplasia
(mean = 5.74, 95% CI, 4.97−6.50), gastritis patients with metaplasia (mean = 4.81, 95%
CI, 3.77−5.84), and gastric cancer cases (mean = 3.38, 95% CI, 2.82−3.94), respectively
(p < 0.0001). Promoter methylation of IRF4 (p < 0.0001), ELMO1 (p < 0.0001), CLIP4
(p < 0.0001), and MSC (p < 0.0001), is also associated with increasing severity from
gastritis with no metaplasia to gastritis with metaplasia and gastric cancer.
Our findings suggest that IRF4, ELMO1, CLIP4 and MSC promoter methylation coupled
with a GDMI>4 are useful molecular tools for gastric cancer risk stratification in endoscopic
biopsies.

BACKGROUND

and others have emphasized the importance of global
DNA hypomethylation in GCs, although little is known
about its role in GC.
H. pylori infection has been correlated with the
progressive accumulation of epigenetic alterations in gastric
mucosa [17]. Promoter hypermethylation in specific tumor
suppressor genes has been associated with H. pylori infection
in the multistep carcinogenetic process by several groups
[27, 28]. Global DNA hypomethylation also increases
throughout the process that leads to the deterioration of
normal gastric mucosa to invasive cancer [29–31].
In the present study we used global, genome wide
and gene-specific DNA methylation analyses to perform
a Phase I Biomarker Development study [32] in order
to examine whether gene specific promoter methylation
biomarkers, together with a global DNA methylation
index (GDMI), could distinguish gastric cancer cases from
controls in endoscopic biopsies.

Gastric cancer (GC) is the fifth most common cancer
in both sexes and the third cause of cancer-related death
around the world [1]. Chronic infection of the stomach
by the bacterium Helicobacter pylori leading to chronic
inflammation is a major attributable risk factor [2],
although less than 2% of H. pylori carriers develop gastric
cancer [3]. The prognosis of GC is closely related to
the stage of disease at the time of diagnosis [4, 5]. The
most widely accepted histopathology-based progression
model for the development of intestinal-type gastric
adenocarcinoma consists of a transition from superficial
gastritis to metaplasia to dysplasia and finally, gastric
adenocarcinoma [6, 7]. When detected at an early stage,
GC is often curable and the five year survival rate is
greater than 90%, whereas the prognosis for advanced GC
is still poor [8]. Early GC is defined as cancer confined
to the mucosa or submucosa regardless of the presence
of lymph node metastasis [9], but due to the non specific
symptomatology and to the difficulty in distinguishing
early GC from benign peptic ulcer or gastritis in the
ambulatory setting, less than 20% of GCs are diagnosed
at an early stage worldwide [10].
Endoscopy is widely used for the early diagnosis of
gastric cancer because of the high accuracy [11], but an
accurate reading depends on the endoscopist’s observation
skills. Apart from conventional endoscopy, magnifying
endoscopy combined with narrow-band imaging (NBI)
has been recently introduced in the diagnosis of early
GC [4, 12] improving the specificity, the sensitivity
and the accuracy of the diagnosis [13, 14]. However,
missed diagnosis of GC on endoscopy is a common
occurrence, with false-negative rates ranging among
5–19% [4, 15, 16]. Consequently, in addition to technical
improvements, the identification of novel biomarkers for
early diagnosis is urgently needed.
Promoter hypermethylation of several tumor
suppressor genes has been correlated with gastric cancer
susceptibility [17]. The literature reports many genes
significantly hypermethylated in cancer tissue compared
with normal tissue of GC subjects [18–20], but relatively
few studies have reported DNA methylation markers for
early detection [21–24]. Furthermore, quantification of
global 5-methylcytosine content [25] and evaluation of
long interspersed nuclear elements (LINEs) by Lee [26]
www.impactjournals.com/oncotarget

RESULTS
Participant characteristics
A total of 376 patients from Peru, mean age 61.2 ± 14.9
years and age range 18–88 years, met the eligibility criteria
and were included in our study (Supplementary Tables
1–2). Patients came to the clinic in Peru with the following
symptoms: heartburn (81.8%), belching (76.4%), distension
(74.2%), abdominal pain (51.1%), nausea (39.6%), and acid
regurgitation (26.3%). There are no significant differences
between age and sex in our randomly created Discovery
and Validation patient groups: Discovery (Global DNA
methylation n = 80; Gene-specific DNA methylation n
= 116) and Validation (Global and Gene-specific DNA
methylation n = 180) (Supplementary Figure 1A). We
performed epigenome-wide DNA methylation analysis of 30
patients selected from the Discovery cohort and Validated
the epigenome-wide DNA methylation results from Peru
using data from 316 participants in the Cancer Genome Atlas
project (Supplementary Figure 1B).

Biomarker development workflow
Global DNA methylation assays were used to
develop the Global DNA Methylation Index (GDMI).
The epigenome-wide arrays were used to identify
38502
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gene-specific promoter regions differentially methylated
in cancer, that can be quantified with methylation specific
PCR (Supplementary Figure 1C).

with more than 10 CpGs were found overlapping the
downstream region of the first exon (16 DMRs), inside the
exon (5 DMRs), covering the exon (3 DMRs), overlapping
the upstream region of the first exon (1 DMR), inside the
intron (1 DMR), and overlapping two exons (1 DMR).

Global DNA methylation and gastric cancer
We observed an inverse association (non-parametric
trend test for ordered groups p < 0.0001) between global
DNA methylation in gastritis patients without metaplasia
(mean = 5.74), gastritis patients with metaplasia
(mean = 4.80), and gastric cancer cases (mean = 3.38)
respectively. (F-test p < 0.0001, Scheffe test p < 0.0001,
when comparing gastritis patients without metaplasia
against GC cases) (Figure 1). In order to assess the GDMI
in high-risk GC clinics, we identified global methylation
> = 6.5 to be associated with gastritis in a random subset
of patients that constituted our discovery set (n = 80).
Using this criterion for identifying gastric cancer cases in
our validation set (n = 180) resulted in 84.78% sensitivity
and 32.82% specificity with 86.00% negative predictive
value (NPV) and 30.71% positive predictive value (PPV)
(p = 0.023). The same cutoff value for GDMI identified
metaplasia > = 10 percent with 87.50% sensitivity, 35.09%
specificity, 95.24% NPV and 15.91% PPV (p = 0.089).
(Supplementary Table 3) When considering the entire
data including discovery and validation sets, we identified
global methylation > = 9 as the best cutoff point with
100% sensitivity and 100% NPV.

Epigenome-wide DNA methylation analyses
using bump hunting in samples from TCGA
We found 695 statistically significant DMRs (FWER
p < 0.05) when we performed epigenome-wide DNA
methylation analyses comparing normal (n = 11) and
cancer (n = 295) samples from TCGA. Most of the DMRs
were observed in chromosome 1 (12%) followed by
chromosome 6 (9%) and chromosome 2 (7%). We found
the DMRs across the following regions of the genome:
inside the gene – 135 DMRs (53%); promoter region 58 DMRs (23%); overlaps 5′ region – 30 DMRs (12%);
downstream from TSS – 19 DMRs (7%); upstream from
TSS – 11 DMRs (4%). The number of individual CpGs
per DMR ranged from 1 to 10. Most of the DMRs had
fewer than 4 CpGs (94%). The DMRs with more than 4
CpGs were found overlapping the downstream region of
the first exon (8 DMRs), inside the exon (6 DMRs), inside
the intron (3 DMRs), and covering the exon (1 DMR).

Gene-specific DNA methylation in DMRs
associated with gastric cancer in Peru and
TCGA datasets

Epigenome-wide DNA methylation analyses
using bump hunting in samples from Peru

We used qMSP to confirm promoter methylation
in four of the 390 statistically significant DMRs (FWER
p < 0.05) common to both the Peru and TCGA sample
sets: IRF4, ELMO1, CLIP4 and MSC. Interestingly, there
is very little difference in the genomic coordinates seen
in the X-axis of the scatterplots that draw the significant
ELMO1 and MSC DMRs identified by two separate
epigenome-wide analyses of the samples from Peru and
TCGA, performed with the bump hunting algorithm in
minfi (Figure 2). This overlap in genomic coordinates for
DMRs identified by separate epigenome-wide analyses
of samples from patients with different ethnic, racial and
socio-economic characteristics, suggest that promoter
methylation of ELMO1 and MSC, may track biological
changes associated with adenocarcinoma, regardless of
life-style and environmental exposures.
Natural log values of promoter methylation in IRF4,
ELMO1, CLIP4 and MSC quantified with qMSP, increase
with age but are not gender dependent (Supplementary
Figure 2). Additionally, promoter methylation levels for
all four genes are highly correlated among themselves,
suggesting the possibility they share a common epigenetic
clustering factor in their clonal evolution (Supplementary
Table 4). Promoter methylation of IRF4 (p < 0.001),
ELMO1 (p < 0.001), CLIP4 (p < 0.001), and MSC
(p < 0.001), is strongly associated with increasing severity

Gastritis (n = 20) vs gastric adenocarcinoma (n = 10)
We used the bump hunting method to perform an
epigenome-wide analysis of the gastric cancer methylome
and identify differentially methylated regions (DMRs)
of biological interest using methylation arrays [33, 34].
For epigenome-wide DNA methylation array studies with
small sample size (n = 3 in each group), bump hunting is
the only recommended method for analysis when DNA
methylation levels are correlated across CpG loci, as they
are in cancer [35]. We found 500 statistically significant
DMRs (FWER p < 0.05) when we performed epigenomewide DNA methylation analyses comparing gastritis
(n = 20) and cancer (n = 10) from Perú. Most of the DMRs
were observed in chromosome 6 (10%) followed by
chromosome 1 (9%), chromosome 19 (8%), chromosome
2 (7%), chromosome 7 (6%), and chromosome 5 (6%).
None of the other chromosomes had more than 5% DMRs.
We found the DMRs across the following regions of the
genome: inside the gene – 431 DMRs (43%); promoter
region - 178 DMRs (18%); overlaps 5′ region – 165
DMRs (16%); downstream from TSS – 114 DMRs (11%);
upstream from TSS – 111 DMRs (11%). The number of
individual CpGs per DMR ranged from 1 to 18. Most of
the DMRs had fewer than 10 CpGs (97%). The DMRs
www.impactjournals.com/oncotarget
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of disease in the histological progression from gastritis
with no metaplasia, to gastritis with metaplasia, to gastric
adenocarcinoma (Figure 3). Using logistic regression,
we observed a statistically significant association
between gastritis patients with metaplasia > = 10% and
promoter methylation of IRF4, ELMO1 and MSC, after
adjusting for age and sex. We also observed a statistically
significant association between gastric cancer diagnosis
and promoter methylation of IRF4, ELMO1, CLIP4 and
MSC, after adjusting for age and sex (Table 1). Together
these results suggest that promoter methylation of IRF4,
ELMO1, CLIP4 and MSC may be part of a gastric cancer
CpG island methylator phenotype (CIMP). The concept
of CIMP)was introduced to refer to a subset of colorectal
carcinomas (CRCs) with widespread methylation of
numerous promoter CpG island loci. Akin to microsatellite
instability (MSI), CIMP is now recognized as one of
the most important molecular carcinogenesis pathways
of CRCs, and CIMP-high (CIMP-H) CRCs have been
characterized for their clinicopathological features [36].

subsequently revised the diagnosis in 30 of the 80 cancer
patients (37.5%) diagnosed by the endoscopists in highrisk clinics, as gastritis patients, using the updated Sydney
system for the histologic classification of gastritis.
Thus, subset analysis was performed on 50 gastric
adenocarcinoma patients in the case study group and 151
gastritis patients in the control study group.
We found that the GDMI discriminates between
diagnosis of gastric cancer and gastritis by endoscopists.
As can be seen in Figure 4A, global DNA methylation
levels were significantly lower in gastric cancer cases
than in gastritis controls (p = 0.002). The mean GDMI for
the controls was 5.7 (95% CI, 4.93–6.41) and the mean
GDMI for the cases was 3.7 (95% CI, 2.99–4.39). The
summary statistics for this comparison are listed in the
Supplementary Table 5.
The pathological characteristics of the gastritis
patients comprising the control study group are
summarized in Supplementary Table 6. The revised
Sydney system for classification of gastritis patients
was used to distinguish between gastritis patients with
superficial and deep Inflammation. Briefly, in gastritis
patients with superficial inflammation the chronic active
infiltration occupies the lamina propria between the
gland crypts but remains above the glands necks. The
glands do not show alterations. In gastritis patients with
deep inflammation the chronic active infiltration extends
beyond the gastric gland neck, occupying the space
between the glands. The glands themselves do not show
alterations.   Gastritis patients with deep inflammation had
a larger percentage of moderate and severe inflammation,
a much higher frequency of atrophy and intestinal
metaplasia, and a much lower incidence of helicobacter
pylori (Supplementary Table 6).
We found that deep inflammation is associated with
global DNA hypomethylation, a hallmark of human cancer:
two-sided p = .097, one-sided p = .0467. (Figure 4B).
The GDMI was able to discriminate gastritis patients

Predictive models with gene-specific methylation
We used the gene specific methylation association
with gastric cancer within the discovery dataset (n = 116)
to estimate separate screening models using IRF4,
ELMO1, CLIP4 or MSC to classify participants in the
validation set who were identified as having a high risk
of gastric cancer based on a GDMI < 6.5. This resulted in
74% correct classification as indicated in Table 2.

Subset analysis of patients misdiagnosed by
endoscopists
Endoscopists diagnosed a total of 201 patients with
high-risk gastric cancer. More than half of the patients
(53%) were diagnosed as gastric cancer patients (n = 80)
by endoscopists. Pathologists at two separate institutions

Figure 1: Boxplot of Global DNA Methylation Index levels in gastritis patients without metaplasia, gastritis patients
with metaplasia and in patients diagnosed with adenocarcinoma of the stomach.
www.impactjournals.com/oncotarget
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according to the depth of inflammation: t-test (p = 0.01)
and Mann-Whitney (p = 0.02). The mean GDMI for
gastritis patients with superficial inflammation was 6.42
(95% CI, 5.3–7.5) compared to 4.65 (95% CI, 3.74–5.57)
for those with deep inflammation. Furthermore, among
gastritis patients with deep inflammation we found a significant

association (p = 0.03) in the GDMI when comparing patients
with and without intestinal metaplasia (Figure 4C). Gastritis
patients with deep inflammation and intestinal metaplasia had
significantly (p = 0.03) lower global DNA methylation levels
(mean = 3.7, 95% CI, 2.75–4.73) when compared to those
without intestinal metaplasia (mean = 5.5, 95% CI, 3.98–6.93).

Figure 2: Significant Differentially Methylated Regions (DMR) identified with the bump hunting algorithm, as
implemented in the minfi package from Bioconductor. Each row represents an individual CpG and each data point represents an

individual patient. (A) Shows the DMR located on chromosome 8, which has the approximate genomic coordinates starting (72754500)
and end (7275700) points. The genomic coordinates of this DMR correspond to the 5′ end of the Musculin (MSC) gene in the hg19
human genome build. This DMR was found to be differentially methylated when comparing the genome-wide epigenome of 10 gastric
adenocarcinoma samples (red) and 20 gastritis samples (black) from patients seen in a high-risk gastric cancer clinic in Peru; (B) shows the
differentially methylated CpGs (each row) located on chromosome 8 with approximate starting (72755800) and end (72756300) genomic
coordinates. The genomic coordinates of this DMR correspond to the 5′ end of the Musculin (MSC) gene and are located within the DMR
in 1A. This DMR was found to be differentially methylated when comparing the genome-wide epigenome of 295 gastric adenocarcinoma
samples (red) and 11 gastritis samples (black) from patients participating in the Cancer Genome Atlas (TCGA) project; (C) shows the DMR
located on chromosome 8 with approximate starting (37488200) and end (37489000) genomic coordinates. The genomic coordinates of this
DMR correspond to the 5’ end of the Engulfment and Cell motility 1 (ELMO1) gene. This DMR was found to be differentially methylated
when comparing the genome-wide epigenome of 10 gastric adenocarcinoma samples (red) and 20 gastritis samples (black) from patients
seen in a high-risk gastric cancer clinic in Peru; (D) shows the differentially methylated CpGs (each row) located on chromosome 8 with
approximate starting (37488250) and end (37488550) genomic coordinates. The genomic coordinates of this DMR correspond to the 5′
end of the Engulfment and Cell motility 1 (ELMO1) gene and are located within the DMR in (A). This DMR was found to be differentially
methylated when comparing the genome-wide epigenome of 295 gastric adenocarcinoma samples (red) and 11 gastritis samples (black)
from patients participating in the Cancer Genome Atlas (TCGA) project.
www.impactjournals.com/oncotarget
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Autosomal epigenome-wide analysis misdiagnosed gastritis (n = 10) vs gastric
adenocarcinoma (n = 10)

gastritis samples misdiagnosed as gastric adenocarcinoma
by endoscopists (n = 10) from Perú. Most of the DMRs
were observed in the X chromosome (27%) followed by
chromosome 6 (10%) and chromosome 1 (6%). None
of the other chromosomes had more than 5% DMRs.
We found the DMRs across the following regions of the
genome: inside the gene – 428 DMRs (46%); promoter
region - 180 DMRs (19%); overlaps 5’ region – 139
DMRs (15%); upstream from TSS – 93 DMRs (10%);
downstream from TSS – 82 DMRs (9%). The number of
individual CpGs per DMR ranged from 1 to 14. Most of
the DMRs had fewer than 7 CpGs (96%). The DMRs with
more than CpGs were found overlapping the downstream
region of the first exon (15 DMRs) and inside the first
exon (11 DMRs).

We found 1448 statistically significant DMRs
(FWER p < 0.05) when we performed epigenome-wide
DNA methylation analyses comparing gastritis samples
misdiagnosed as gastric adenocarcinoma by endoscopists
(n = 10) and gastric adenocarcinoma (n = 10) from Perú.
Most of the DMRs were observed in the X chromosome
(36%) followed by chromosome 6 (6%) and the Y
chromosome (6%). None of the other chromosomes had
more than 5% DMRs. We found the DMRs across the
following regions of the genome: inside the gene – 639
DMRs (44%); overlaps 5′ region - 295 DMRs (20%);
promoter region – 260 DMRs (18%); downstream from
TSS – 133 DMRs (9%); upstream from TSS – 118 DMRs
(8%). The number of individual CpGs per DMR ranged
from 1 to 18. Most of the DMRs had fewer than 10 CpGs
(96%). The DMRs with more than 10 CpGs were found
overlapping the downstream region of the first exon (39
DMRs), inside the exon (10 DMRs), and covering the first
exon (5 DMRs).

DISCUSSION
Ours is the first study that combines global,
epigenome-wide and gene-specific methylation analyses
of the gastric cancer epigenome in endoscopic biopsies
obtained from ambulatory high-risk gastric cancer clinics.
Our findings suggest that promoter methylation of CLIP4,
IRF4, ELMO1, and MSC, together with a GDMI > 4, is a
useful molecular panel for gastric cancer risk stratification
in endoscopic biopsies (Figure 5).
Promoter methylation of CAP-Gly Domain
Containing Linker Protein Family Member 4 (CLIP4) is
the only one, of the four genes in our panel, which has
been reported as methylated in gastric cancer in previous

Autosomal epigenome-wide-misdiagnosed
gastritis (n = 10) gastritis (n = 10)
We found 392 statistically significant DMRs (FWER
p < 0.05) when we performed epigenome-wide DNA
methylation analyses comparing gastritis (n = 10) and

Figure 3: Boxplot of gene-specific promoter methylation in gastritis patients without metaplasia, gastritis patients with
metaplasia and in patients diagnosed with adenocarcinoma of the stomach.
www.impactjournals.com/oncotarget
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Table 1: Promoter DNA methylation association with gastric cancer and metaplasia > = 10%
Odds Ratio
Gastric cancer (unadjusted)
gmeth_ln
0.49
IRF4_ln
2.37
ELMO1_ln
2.00
CLIP4_ln
1.90
MSC_ln
1.76
Gastric cancer (age, sex adj)
gmeth_ln
0.46
IRF4_ln
2.21
ELMO1_ln
1.95
CLIP4_ln
1.78
MSC_ln
1.67
Mplasia > = 10% (unadj)
gmeth_ln
0.50
IRF4_ln
2.49
ELMO1_ln
2.44
CLIP4_ln
2.08
MSC_ln
2.61
Mplasia > = 10% (age, sex adj)
gmeth_ln
0.43
IRF4_ln
1.89
ELMO1_ln
1.88
CLIP4_ln
1.57
MSC_ln
1.98

Std. Err.

95% Conf. interval

Pseudo R2

Obs

P

0.10
0.38
0.27
0.27
0.24

0.32–0.73
1.72–3.25
1.54–2.59
1.43–2.51
1.35–2.30

0.04
0.10
0.06
0.07
0.06

257
291
286
290
291

< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001

0.10
0.37
0.27
0.26
0.24

0.30–0.71
1.60–3.07
1.48–2.57
1.33–2.38
1.26–2.21

0.09
0.12
0.12
0.09
0.09

249
276
271
275
276

< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001

0.15
0.68
0.55
0.53
0.64

0.29–0.89
1.46–4.25
1.57–3.79
1.27–3.41
1.61–4.24

0.04
0.08
0.12
0.06
0.12

183
188
183
187
188

0.018
0.001
< 0.0001
0.004
< 0.0001

0.13
0.58
0.47
0.43
0.54

0.23–0.79
1.03–3.44
1.15–3.08
0.92–2.69
1.17–3.36

0.09
0.11
0.13
0.10
0.13

176
177
172
176
177

0.007
0.038
0.012
0.098
0.011

studies. CLIP4, also known as UBASH3A or TULA,
is a member of the T-cell ubiquitin ligand family and
suppresses T-cell signaling. CLIP4 can facilitate growth
factor withdrawal-induced apoptosis in T-cells [37] and
promote the accumulation of various activated target
receptors, such as T-cell receptors, epidermal growth
factor (EGF) receptor, and platelet-derived growth factor
beta-receptor [38, 39], which can induce cell invasiveness
and metastasis. CLIP4 also activates the EGFR signaling
pathway by downregulation of the EGF receptor [40]. In
other cells, CLIP4 activates Syk [41], a member of the
protein tyrosine kinase family linked with cell motility and
increased cell migration [42–44].
Interferon regulatory factors (IRFs) are a family
of transcriptional regulators defined by a characteristic
homology in their DNA-binding domain. They play an
important role in the regulation of various genes (such
as IFNs, interleukins, MHC class I/II), apoptosis and
differentiation/maturation [45, 46]. Interferon regulatory
factor 4 (IRF-4) is one member with very restricted
expression pattern and plays a crucial role in the function
of immune cells. Predominately B- and activated
T-lymphocytes are IRF-4 positive [47]. Deletion of IRF-4
www.impactjournals.com/oncotarget

causes failure to develop mature and functionally active
B- and T-lymphocytes [48].
Engulfment and cell motility 1 (ELMO1) plays a
role in promoting cancer cell migration and invasion in
malignant glioma [49]. ELMO1 promoter methylation
roles are also reported in human colorectal cancer [50],
kidney disease [51], and rheumatoid arthritis [52]. The
protein produced by ELMO1 belongs to a protein family
that interacts with dedicator of cytokinesis proteins to
promote phagocytosis and cell migration.
Musculin, a human protein encoded by the MSC
gene, is a transcriptional repressor capable of binding an
E-box element either as a homodimer or as a heterodimer
with E2A in vitro. The encoded protein also forms
heterodimers with E2A proteins in vivo. This protein
is capable of inhibiting the transactivation capability
of E47, an E2A protein, in mammalian cells. This gene
is a downstream target of the B-cell receptor signal
transduction pathway [53, 54]. MSC (and probably
TCF21) is located together with TBX1 and PITX2
upstream of myogenic regulatory factor 5 (Myf5) and
Myogenic Differentiation 1 (MyoD 1). MSC regulates
the levels of expression of Myf5 and MyoD by direct
38507
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Table 2: Odds ratios and coefficient of models predicting GC risk using IRF4, ELMO1, CLIP4
or MSC
IRF4
const
ELMO1
const
CLIP4
const
MSC
const

OR

SE

1.398

0.236

1.003

95% Conf int
1.947

1.195

0.104

1.007

1.418

1.136

0.091

0.971

1.328

1.249

0.155

0.979

1.594

Coef

SE

0.335
−0.317
0.178
−0.293
0.127
−0.225
0.223
−0.334

0.169
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Promoter methylation of RNF180, DAPK1 and
SFRP2 can be detected in plasma DNA of patients with
gastric cancer [71]. Promoter methylation of E-cadherin
in a subset of our gastric cancer patients is consistent
with aggressiveness and metastasis of gastric cancer [72].
HLTF methylation plays a role in the early stages of gastric
carcinogenesis in patients with family histories and may be
a valuable susceptible marker for the risk of gastric cancer
in individuals with family predisposition [73].
Several studies have been carried out examining
altered methylation levels in normal gastric mucosa and
GC attempting to identify possible biomarkers for the
surveillance of high-risk patients. Bernal et al., showed
that aberrant hypermethylation of the Reprimo gene
represents a potential biomarker for the early detection of
gastric cancer with differential methylation in the plasma
DNA between controls and cases. Moreover, the signetring cell-type of GC was associated with a methylation
profile of eight specific genes [74]. Also, promoter
methylation levels are correlated with loss of expression of
Reprimo in gastric cancer tissues, progression from stage I
to stages II–IV and lymph node metastasis [75].
Other studies, using epigenome-wide DNA
methylation arrays for discovery and qMSP for validation,
unveiled the role of promoter methylation in in endoscopic
samples taken from high-risk clinics patients diagnosed
with gastritis and gastric carcinogenesis. Shin et al. reported
the promoter methylation of MOS, DCC, CRK, and PTPN6
in gastric cancer [76]. Epigenome-wide DNA methylation
arrays have also identified the role of DVL2 and ETS1
methylation in diffuse- and mixed-types of early gastric
cancers [77]. On the other hand, C19orf35 and CNRIP1
were related to the diffuse type rather than intestinal type,
and GAL3ST2 and ITGA3 were related to the mixed-type
rather than the other two types [77]. The methylation of
other genes, CLIP4, XKR6, CCDC57, MAML3 and SDC2,
was related with one or more of the following variables:
age, tumor location, and Helicobacter pylori infection,
rather than with the histologic subtype [77].
We also investigated the role of GDMI as biomarker
for gastric cancer carcinogenesis. The lower GDMI levels

interactions through ubiquitin-activating enzymes E1
C-terminal related (ECR-1) and the distal regulatory
region (DRR), respectively [55]. Methylation of Musculin
has not been previously reported.
Methylation of individual dinucleotide cytosineguanosine motifs (CpG) in CpG islands located in
promoter regions, is one of the mechanisms of gene
regulation in mammals and a common event of gene
silencing in cancer. Gain of methylation of CpG islands
together with global loss of methylation are frequently
observed events in every tumor cell, in contrast to normal
cells [56, 57]. De novo DNA methylation of genes with
important cellular regulatory functions, such as cell cycle,
DNA repair, apoptosis and tumor suppressor genes, is
involved in tumorigenesis [58–60].
Several gene specific DNA methylation events seen
in gastritis and gastric cancer patients may be associated
with Helicobacter pylori infection and the progression
of dysplastic lesions to adenocarcinoma of the stomach,
but the evidence is contradictory and non-conclusive yet.
Promoter methylation in a subset of gastric cancer patients
is associated with the CpG island methylator phenotype,
which includes methylation of such genes as CDKN2A and
hMLH1 [61, 62]. Promoter methylation in Helicobacter
pylori or Epstein-Barr virus infected gastric mucosae
may play a functional role and lead to gastric cancer risk
[27, 63–65]. Inactivation of COX-2, HMLH1 and CDKN2A
by promoter methylation depends on the Helicobacter
pylori genotype and occurs by distinct pathways, according
to the histological subtype and tumor location [66].
Promoter methylation of MGMT is related to gastric
cancer risk, distant metastasis, and lymph node metastasis,
which indicates that MGMT promoter methylation may
play an important role in gastric cancer development
[67]. Promoter methylation of ASC/TMS1 is associated
with poor prognosis of patients with gastric cancer [68].
RBL1 is methylated in patients with intestinal metaplasia,
with or without Helicobacter pylori, and in gastric
cancer patients [69]. Promoter methylation of RNF180 is
associated with Helicobacter pylori infection and serves
as a marker for gastric cancer and atrophic gastritis [70].
www.impactjournals.com/oncotarget
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Figure 4:  (A) Boxplots of Global DNA Methylation Index levels in a subset of adenocarcinoma cases and gastritis controls that were

diagnosed by endoscopists in the clinic; (B) Boxplots of Global DNA Methylation Index levels in a subset of gastritis patients dichotomized
according to the depth of superficial and deep inflammation; (C) Boxplots of Global DNA Methylation Index levels in deep inflammation
cases according to the presence of intestinal metaplasia.
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we observed in gastric cancer biopsies are consistent with
the observations made by Lee et al, namely that gastric
epithelial dysplasia and intramucosal cancer tissues had
significantly lower levels of LINE-1 methylation than
adjacent normal gastric tissues [26]. LINE-1 is a surrogate
marker of global DNA methylation that measures
methylation in a subset of repetitive elements across the
genome. The GDMI is a better indicator of global DNA
methylation levels than LINE1, because it quantifies
DNA methylation across the entire human genome. Our
study further shows that the GDMI can discriminate
gastritis patients with different degrees of inflammation
and metaplasia. This interesting molecular difference
suggests the ability to potentially discriminate between
different degrees of gastritis severity, intestinal metaplasia
and gastric adenocarcinoma, solely based on global DNA
methylation levels in gastric mucosa epithelium.
The GDMI can discriminate the depth of
inflammation, as gastritis patients with deep inflammation
exhibit lower GDMI than those with superficial
inflammation, suggesting that at the molecular levels
these patients may be the most prone to progress towards
gastric cancer. We also observed interesting results when
contrasting patients with intestinal metaplasia less than
or greater than 10%. Patients with intestinal metaplasia
> = 10% had lower GDMI (p = 0.013). We also found
that the gastritis patients who were originally diagnosed
with cancer by the endoscopists harbor lower GDMI
values than the gastritis patients, classified as such by
both the endoscopists and the pathologists. Furthermore,
these gastritis patients misdiagnosed as cancer patients by
endoscopists had a similar global DNA methylation profile

as adenocarcinoma patients. These data support the notion
that the misdiagnosed cases have an underlying oncogenic
molecular process and are most likely to deteriorate to
cancer. It should be noted that in all of our models of
gastric cancer, sex was a significant covariate while age
was not. This does not reflect absence of association
between gastric cancer and age, but rather the correlation
between age and GDMI, which partially accounts for the
covariation between age and the outcome, masking some
of the contribution by age. By contrast, sex and GDMI
were independent.
Only a few studies have examined global DNA
hypomethylation in gastric cancer by itself, under the
rationale that hypomethylation is the earliest epigenomic
event that signifies the transition from a normal to a
malignant phenotype. While the precise mechanisms
that lead to a global loss of methylation patterns in
cancer are still to be elucidated, it is evident that global
DNA hypomethylation is already present in the early
stages of gastric carcinogenesis and may play various
roles in the biologic progression of gastric cancer
lesions. Genome wide hypomethylation and regional
hypermethylation have been shown to occur in an
enlarged-fold gastritis that may also contribute to the
tumorigenesis of diffuse-type gastric cancers [78]. Another
study found that global DNA hypomethylation, assessed
by incubating DNA with (3H)-S-adenosylmethionine
and Sss1 methylase, also occurs in the early stages of
gastric carcinogenesis up to chronic atrophic gastritis,
but is lost as a marker in gastric cancer. They also
found that global hypomethylation of DNA increased
substantially with severe atrophy (p = 0.01) or

Figure 5: Graphical representation of histologic and molecular progression stages proposed for gastric adenocarcinoma,
with mean values for global and gene-specific promoter methylation of IRF4, ELMO1, CLIP4 and MSC.
www.impactjournals.com/oncotarget
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Tissue samples and DNA extraction

with type III intestinal metaplasia (p = 0.15), thus
leading the authors to propose it as a useful biomarker
of gastric neoplasia, and monitoring the response to
chemopreventive agents [79]. Another study found that
LINE-1 hypomethylation is significantly associated
with H. pylori infection, supporting a role for LINE-1
methylation level as viable epigenetic marker of gastric
mucosae induced by H. pylori infection [31]. Collectively,
these studies suggest that the GDMI may be an epigenomic
reflection of important early cellular events in gastric
cancer initiation and progression [80, 7].
Much as with mutational data, our data on global,
epigenome-wide and promoter DNA methylation
alterations in gastric premalignant lesions, should
encourage further analyses of differential methylation
in specific genetic loci associated with over and under
expression in signaling pathways that contribute to gastric
cancer development or progression, and how these loci
match or differ from those implicated in other types of
cancers, all of which in turn could have implications for
development of new early detection and diagnostic tools
for the precision medicine era.

Two endoscopy biopsies were taken from each
patient. Biopsies were obtained from the cancerous
lesion for the cases and from the gastric antrum for
the controls, frozen at −70 and sent for processing and
storage in the Universidad Peruana Cayetano Heredia.
Gastric mucosa tissue was fixed in 10% formalin buffer
and embedded in paraffin for microscopy histological
examination. Hematoxylin and eosin-stained histological
slides were scored using the Sydney System (Lash, 2013
#166). Biopsies indicative of intestinal metaplasia were
stained with PAS. H. pylori lesions were identified by
Warthin Starry silver stain. All neoplastic tissues used in
this study were classified as gastric adenocarcinoma by
histopathology.
DNA was extracted from the frozen tissue samples
using the QIAmp DNA Mini Kit (QIAGEN, Germany)
and stored at −20°C until use in the Universidad
Peruana Cayetano Heredia. DNA concentrations were
measured using Nanodrop ND-1000 spectrophotometer.
Five micrograms of DNA were sent to Johns Hopkins
University for DNA methylation analyses.

MATERIALS AND METHODS

Global DNA methylation analysis

Participants

Global DNA methylation levels were determined
by ELISA using the MDQ1, Imprint® Methylated DNA
Quantification Kit (Sigma, USA) according to the
manufacturer’s instructions. Each analysis for sample(s) and
control DNA was performed in duplicate and the average
of the absorbance readings at 450nm (A450) was used for
calculations. The GDMI for each sample was calculated
according to the equation: [(A450avSample - A450avBlank)/
(A450avMethylated Control DNA - A450avBlank)] × 100.

The study population consists of a prospective,
observational cohort initiated in 2006 and closed in
June 2009. We recruited 576 patients who were seen by
gastrointestinal endoscopists in high-risk gastric cancer
clinics of the Gastroenterology Divisions at three hospitals
in Lima: Hospital Nacional Arzobispo Loayza, Hospital
Nacional Dos de Mayo, and the cancer-specialized
Instituto Nacional de Enfermedades Neoplásicas. The
inclusion criterion for the gastritis controls in the study
was for the patients to have gastro-duodenal symptoms
(ICD9-CM code 535) whereas for the cases, the inclusion
criterion was to have a clinical diagnosis of gastric cancer
(ICD9-CM code 151), all determined by pathologists at
two different institutions in Peru. A pathologist at Johns
Hopkins School of Medicine reviewed a random sample
of slides. All patients underwent endoscopic diagnosis
and biopsy. From this cohort, 376 study patients had DNA
samples adequate for analysis. Participants were randomly
assigned to three groups: a Discovery group for GDMI
analysis; a Discovery group for epigenome-wide and genespecific DNA methylation analysis; and a Validation group
for combined GDMI and gene-specific promoter DNA
methylation analysis. The Institutional Review Boards
of the Instituto Nacional de Neoplásicas, the National
Hospital Arzobispo Loayza, the Hospital Nacional Dos
de Mayo, the Universidad Peruana Cayetano Heredia and
the Johns Hopkins School of Medicine (NA_00020633)
approved the research protocols. Informed written consent
was obtained from all patients included in the study.
www.impactjournals.com/oncotarget

Epigenome-wide DNA methylation analysis
The HumanMethylation450K DNA BeadChip
assay was used to perform unbiased epigenome-wide
DNA methylation analysis. Bisulfite modification of
genomic DNA (2 μg) was performed with EpiTect
Bisulfite Kit (QIAGEN) according to the manufacturer’s
protocol. We hybridized bisulfite converted DNA to the
HumanMethylation450K array to identify differentially
methylated regions (DMRs) in gastritis samples (n = 10),
gastritis samples misdiagnosed as cancer by endoscopists
(n = 10) and cancer samples (n = 10). To validate these
results we performed an unbiased epigenome-wide DNA
methylation analysis to identify DMRs in gastric cancer
samples (n = 295) from the Cancer Genome Atlas project
(TCGA) and gastritis controls (n = 20) from Perú.
We imported the data into R using the illuminaio
package [81]. For data normalization we used the minfi
package to apply the Noob background subtraction and
dye-bias correction [82] followed by normalization and
38511
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identification of DMRs between cases and controls using
the bump hunting method in minfi [83]. The minfi package
provides tools for analyzing Illumina’s methylation
arrays and includes methods for preprocessing, quality
assessment, and detection of differentially methylated
regions from the kilobase to the megabase scale. We
performed pre-processing with the minfi package applying
a version of subset quantile normalization to the Meth
and Unmeth intensities separately. The distribution of
type I and type II probes were forced to be the same
by first quantile normalizing the type II probes across
samples and then interpolating a reference distribution
to which the type I probes are normalized. The stratified
quantile normalization method is implemented by the
preprocessQuantile function (the function does no
background correction and removes zeros using the
fix2 MethOutlier function). This algorithm relies on the
assumptions necessary for quantile normalization and
involves both within and between sample normalization.
After normalization the bump hunting method was carried
out by first fitting a linear regression model for each
locus before smoothing the coefficient within clusters
along the genome to identify bumps. More specifically,
for each locus, a linear model was used to estimate the
coefficient of difference in methylation levels between
the cancer group and the normal groups. After fitting the
linear regression model, the bump hunting method was
implemented to estimate the regions for which there were
statistically significant differences in methylation levels
(Differentially Methylated Regions or DMRs) between the
cancer group and the normal groups. Statistical uncertainty
was assigned to each DMR using permutation tests
generate a raw p-value from the bump hunting method,
and an adjusted p-value generated from the minfi package
using Storey’s procedure (bump hunting q-value). We
then intersected the statistically significant DMRs (FWER
p < 0.05) that discriminate gastric cancer from gastritis in
samples from Peru and TCGA.

hunting algorithm and 1000 bases up- and downstream
was obtained from the UCSC Genome Browser [85].
The primers and hybridization probes for methylation
analysis were designed based on this sequence by using
MethPrimer [86]. All primer and probe sequences are
listed in Supplementary Table 8. Fluorogenic PCR
reactions were performed in duplicates in a reaction
volume of 20 μl that contained 3 μl of bisulfite-modified
DNA; 600 nM of each primer; 200 nM probe; 0.75 U of
platinum Taq polymerase (Invitrogen, MD, USA); 200 μM
of each dATP, dCTP, dGTP and dTTP; 200 nM ROX
dye reference; 1X buffer (16.6 mM ammonium sulfate;
67 mM Trizma [Sigma]; 6.7 mM of magnesium chloride;
10 mM of mercaptoethanol and 0.1% dimethyl-sulfoxide).
Amplifications were performed using the reaction profile:
95°C for 3 min, followed by 50 cycles at 95°C for 15 s and
60°C for 1 min in a 7900 HT sequence detector (Applied
Biosystems, CA, USA) and were analyzed by a sequence
detector system (SDS 2.4; Applied Biosystems).

Statistical analysis
Patients with adequate samples for analysis were
randomly divided into a Discovery cohort for separate
global DNA methylation (n = 80) and gene-specific DNA
methylation (n = 116) analyses and a Validation cohort
for combined global and gene-specific DNA methylation
analyses (Supplementary Figure 3). The revised Sydney
criteria were used for gastritis classification (Lash, 2013
#166). Analyses were adjusted for Helicobacter pylori
infection status, age and sex. Disease status was a binary
variable indicating gastritis vs gastric adenocarcinoma
based on pathological diagnosis. Subset analyses were
performed in a subset of samples that were misdiagnosed
by endoscopists. Global DNA methylation was measured
on genomic DNA and analyzed as a continuous variable.
Epigenome-wide and gene-specific DNA methylation
was measured on bisulfite converted DNA and analyzed
as continuous variables. Quantitative methylation specific
PCR was used to measure promoter methylation of IRF4,
ELMO1, and MSC.
The primary outcome indicator was a binary variable
to identify gastric adenocarcinoma (GC) from gastritis
cases. We also used the level of metaplasia as a proxy to
identify gastritis patients with higher risk of developing
GC. We conducted ordinary and logistic regression and
analysis of variance, Fisher exact test and other tests of
hypothesis to analyze the data. All data was analyzed and
managed using STATA 13 (Statacorp, Texas, USA) and
results with a p < 0.05 were considered as statistically
significant. Student’s t-test or ANOVA test were used
for analyzing distributions or variances, respectively.
Additional global and epigenome-wide analyses were
performed in subset of patients from Peru (n = 201)
for whom we also had a diagnosis provided by the
endoscopists. In addition, epigenome-wide analyses were

Gene-specific DNA methylation analyses
We selected four of the genes that had the greater
variance and the largest number of CpGs in the DMR
window, from the list of significant DMRs (FWER
p < 0.05) common to both the DMR results from the Peru
and TCGA epigenome-wide analyses: IRF4 (interferon
regulatory factor 4); ELMO1 (encodes Engulfment
and cell motility protein 1); CLIP4 (CAP-Gly domain
containing linker protein family member 4); and MSC
(encoding Musculin protein). We designed primers and
probes to quantify promoter methylation of these four
genes using fluorogenic quantitative methylation specific
PCR (qMSP), as previously described [84].
Briefly, bisulfite-modified DNA was used as
a template for qMSP. The genomic sequence for the
genes within the DMRs identified with the bump
www.impactjournals.com/oncotarget
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performed in 295 gastric cancer samples and 11 normal
gastric epithelium samples from the Cancer Genome Atlas
(TCGA) project.
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